Psoriatic Arthritis Treatment Market: By Drug Class, TNF Alfa Inhibitors, Corticosteroids, Interleukin Inhibitors, PDE4 Inhibitors, Others), By Disease Indication, By Route of Administration, By Distribution Channel, and Region Forecast 2019-2030

Psoriatic Arthritis Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Non-Steroidal Anti Inflammatory Drugs (NSAIDs), TNF Alfa Inhibitors, Corticosteroids, Interleukin Inhibitors, PDE4 Inhibitors, Others), By Disease Indication (Mild, Moderate, Severe), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region Forecast 2019-2030

Psoriatic Arthritis Treatment Market size was valued at US$ 7.61 billion in 2023 and is poised to grow at a CAGR of 9.5% from 2024-2030. Psoriatic Arthritis is a form of arthritis developed in people affected by psoriasis. It causes affected joints to become swollen, stiff, and painful. Most of the people affected by psoriasis are first and later diagnosed with psoriatic arthritis. Approximately 15-25% of people with psoriasis can develop psoriatic arthritis. Symptoms associated with psoriatic arthritis include swollen joints, low back pain, nail pitting, conjunctivitis, and foot pain among others.

Psoriatic arthritis is a type of arthritis that affects some people who suffer from psoriasis, a dyskinesia ailment that causes red patches with silvery scales. The majority of people first acquire psoriasis before being diagnosed with psoriatic arthritis. Joint difficulties, on the other hand, might occasionally start before skin patches emerge. When the immune system attacks healthy cells and tissue, this disease develops. Inflammation of the joints, as well as an overproduction of skin cells, are caused by an aberrant immunological response.

Global Psoriatic Arthritis Psa Treatments Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

9.5%

Largest Market

Europe

Fastest Growing Market

North-America

Psoriatic Arthritis Treatment Market Dynamics

Increase in the prevalence of psoriasis results to rise in number of psoriatic arthritis patients is a key factor enhance the revenue of psoriatic arthritis market. Moreover, rise in R&D for the innovation of newer products, pipeline drugs under various stages of clinical trials, frequent product launchings by the market players, and increase in the awareness about psoriatic arthritis treatment among the healthcare professionals are expected to drive the global psoriatic treatment market over the forecast years. However, stringent regulations for the product approval, high cost of treatment, entry of biosimilars into market, and lack of standardization tools for diagnosis and treatment are restrain the growth of the market.

Global Psoriatic Arthritis Psa Treatments Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 7.61 billion

Market CAGR

9.5%

By Drug Class

  • Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
  • TNF Alfa Inhibitors
  • Corticosteroids
  • Interleukin Inhibitors
  • PDE4 Inhibitors
  • Others

By Disease Condition

  • Mild
  • Moderate
  • Severe

By Route Administration

  • Oral
  • Parenteral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The psoriatic arthritis psa treatments market report provides granular level information about the market size, regional market share, historic market (2019 to 2023) and forecast (2024 to 2030)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startups details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis 

Download Free Sample Report

Frequently Asked Questions

The global psoriatic arthritis psa treatments market size was valued at US$ 7.61 billion in 2023 and is projected to grow at a CAGR of 9.5% from 2024 to 2030.

The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The market key players are: Bristol Myers Squibb Company (U.S.), Hoffmann La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Amgen, Inc. (U.S.), Hohnson & Johnson Services, Inc. (U.S.)

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Psoriatic Arthritis Psa Treatments Market Introduction 
2.1.Global Psoriatic Arthritis Psa Treatments Market  - Taxonomy
2.2.Global Psoriatic Arthritis Psa Treatments Market  - Definitions
2.2.1.Drug Class
2.2.2.Disease Condition
2.2.3.Route Administration
2.2.4.Distribution Channel
2.2.5.Region
3. Global Psoriatic Arthritis Psa Treatments Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Psoriatic Arthritis Psa Treatments Market Analysis, 2019-2023 and Forecast 2024-2030
4.1.  Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Psoriatic Arthritis Psa Treatments Market  By Drug Class, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
5.1. Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. TNF Alfa Inhibitors
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Corticosteroids
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Interleukin Inhibitors
5.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. PDE4 Inhibitors
5.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Others
5.6.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6. Global Psoriatic Arthritis Psa Treatments Market  By Disease Condition, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
6.1. Mild
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Moderate
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Severe
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Psoriatic Arthritis Psa Treatments Market  By Route Administration, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Parenteral
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Topical
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Psoriatic Arthritis Psa Treatments Market  By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacies
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9. Global Psoriatic Arthritis Psa Treatments Market  By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10. North America Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
10.1. Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
10.1.2.TNF Alfa Inhibitors
10.1.3.Corticosteroids
10.1.4.Interleukin Inhibitors
10.1.5.PDE4 Inhibitors
10.1.6.Others
10.2.  Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Mild
10.2.2.Moderate
10.2.3.Severe
10.3.  Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Parenteral
10.3.3.Topical
10.4.  Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Online Pharmacies
10.5.  Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11. Europe Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
11.1.2.TNF Alfa Inhibitors
11.1.3.Corticosteroids
11.1.4.Interleukin Inhibitors
11.1.5.PDE4 Inhibitors
11.1.6.Others
11.2.  Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Mild
11.2.2.Moderate
11.2.3.Severe
11.3.  Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Parenteral
11.3.3.Topical
11.4.  Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Online Pharmacies
11.5.  Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12. Asia Pacific (APAC) Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
12.1.2.TNF Alfa Inhibitors
12.1.3.Corticosteroids
12.1.4.Interleukin Inhibitors
12.1.5.PDE4 Inhibitors
12.1.6.Others
12.2.  Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Mild
12.2.2.Moderate
12.2.3.Severe
12.3.  Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Parenteral
12.3.3.Topical
12.4.  Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Online Pharmacies
12.5.  Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13. Middle East and Africa (MEA) Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
13.1.2.TNF Alfa Inhibitors
13.1.3.Corticosteroids
13.1.4.Interleukin Inhibitors
13.1.5.PDE4 Inhibitors
13.1.6.Others
13.2.  Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Mild
13.2.2.Moderate
13.2.3.Severe
13.3.  Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Parenteral
13.3.3.Topical
13.4.  Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Online Pharmacies
13.5.  Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14. Latin America Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
14.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
14.1.2.TNF Alfa Inhibitors
14.1.3.Corticosteroids
14.1.4.Interleukin Inhibitors
14.1.5.PDE4 Inhibitors
14.1.6.Others
14.2.  Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Mild
14.2.2.Moderate
14.2.3.Severe
14.3.  Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Parenteral
14.3.3.Topical
14.4.  Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Online Pharmacies
14.5.  Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Bristol-Myers Squibb Company (U.S.)
15.2.2.Hoffmann La Roche Ltd. (Switzerland)
15.2.3.Novartis AG (Switzerland)
15.2.4.Amgen, Inc. (U.S.)
15.2.5.Hohnson & Johnson Services, Inc. (U.S.)
15.2.6.AbbVie Inc. (U.S.)
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Bristol-Myers Squibb Company (U.S.)
  • Hoffmann La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • Amgen, Inc. (U.S.)
  • Hohnson & Johnson Services, Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Eli Lilly & Co. (U.S.)
  • UCB Inc. (Belgium)
  • Celgene Corporation (U.S.)
  • Valeant Pharmaceuticals International, Inc. (U.S.)

Related Industry Reports